Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


The molecular diversity of Luminal A breast tumors.

Ciriello G, Sinha R, Hoadley KA, Jacobsen AS, Reva B, Perou CM, Sander C, Schultz N.

Breast Cancer Res Treat. 2013 Oct;141(3):409-20. doi: 10.1007/s10549-013-2699-3. Epub 2013 Oct 6.


Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.

Boyault S, Drouet Y, Navarro C, Bachelot T, Lasset C, Treilleux I, Tabone E, Puisieux A, Wang Q.

Breast Cancer Res Treat. 2012 Feb;132(1):29-39. doi: 10.1007/s10549-011-1518-y. Epub 2011 Apr 22.


Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.

Deng L, Chen J, Zhong XR, Luo T, Wang YP, Huang HF, Yin LJ, Qiu Y, Bu H, Lv Q, Zheng H.

PLoS One. 2015 Mar 27;10(3):e0120511. doi: 10.1371/journal.pone.0120511. eCollection 2015.


Comprehensive molecular portraits of human breast tumours.

Cancer Genome Atlas Network.

Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.


GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.

Jiang YZ, Yu KD, Zuo WJ, Peng WT, Shao ZM.

Cancer. 2014 May 1;120(9):1329-37. doi: 10.1002/cncr.28566. Epub 2014 Jan 29.


DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival.

Conway K, Edmiston SN, May R, Kuan PF, Chu H, Bryant C, Tse CK, Swift-Scanlan T, Geradts J, Troester MA, Millikan RC.

Breast Cancer Res. 2014 Oct 7;16(5):450. doi: 10.1186/s13058-014-0450-6.


PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.

López-Knowles E, O'Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P, Daly RJ, Musgrove EA, Sutherland RL.

Int J Cancer. 2010 Mar 1;126(5):1121-31. doi: 10.1002/ijc.24831.


PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.

Flatley E, Ang D, Warrick A, Beadling C, Corless CL, Troxell ML.

Hum Pathol. 2013 Jul;44(7):1320-7. doi: 10.1016/j.humpath.2012.10.018. Epub 2013 Jan 24.


ESPL1 is a candidate oncogene of luminal B breast cancers.

Finetti P, Guille A, Adelaide J, Birnbaum D, Chaffanet M, Bertucci F.

Breast Cancer Res Treat. 2014 Aug;147(1):51-9. doi: 10.1007/s10549-014-3070-z. Epub 2014 Aug 3.


Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.

Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, Kilpivaara O, Luts L, Heikkilä P, Aittomäki K, Blomqvist C, Loman N, Malmström P, Olsson H, Johannsson OT, Arason A, Nevanlinna H, Barkardottir RB, Borg A.

Breast Cancer Res. 2010;12(3):R42. doi: 10.1186/bcr2596. Epub 2010 Jun 24.


Total Survivin and acetylated Survivin correlate with distinct molecular subtypes of breast cancer.

Yakirevich E, Samkari A, Holloway MP, Lu S, Singh K, Yu J, Fenton MA, Altura RA.

Hum Pathol. 2012 Jun;43(6):865-73. doi: 10.1016/j.humpath.2011.07.014. Epub 2011 Nov 4.


p53 in breast cancer subtypes and new insights into response to chemotherapy.

Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, Espié M, de Thé H.

Breast. 2013 Aug;22 Suppl 2:S27-9. doi: 10.1016/j.breast.2013.07.005. Review.


PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases.

Michelucci A, Di Cristofano C, Lami A, Collecchi P, Caligo A, Decarli N, Leopizzi M, Aretini P, Bertacca G, Porta RP, Ricci S, Della Rocca C, Stanta G, Bevilacqua G, Cavazzana A.

Diagn Mol Pathol. 2009 Dec;18(4):200-5. doi: 10.1097/PDM.0b013e31818e5fa4.


An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.

Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, Jones C, Lord CJ, Vatcheva R, Rodriguez-Pinilla SM, Palacios J, Ashworth A, Reis-Filho JS.

Breast Cancer Res Treat. 2010 Jun;121(3):575-89. doi: 10.1007/s10549-009-0501-3. Epub 2009 Aug 18.


Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.

Dunlap J, Le C, Shukla A, Patterson J, Presnell A, Heinrich MC, Corless CL, Troxell ML.

Breast Cancer Res Treat. 2010 Apr;120(2):409-18. doi: 10.1007/s10549-009-0406-1. Epub 2009 May 6.


Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.

Kehr EL, Jorns JM, Ang D, Warrick A, Neff T, Degnin M, Lewis R, Beadling C, Corless CL, Troxell ML.

Hum Pathol. 2012 Dec;43(12):2207-12. doi: 10.1016/j.humpath.2012.03.012. Epub 2012 Jun 15.


Polarity gene alterations in pure invasive micropapillary carcinomas of the breast.

Gruel N, Benhamo V, Bhalshankar J, Popova T, Fréneaux P, Arnould L, Mariani O, Stern MH, Raynal V, Sastre-Garau X, Rouzier R, Delattre O, Vincent-Salomon A.

Breast Cancer Res. 2014 May 8;16(3):R46. doi: 10.1186/bcr3653.


TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.

Silwal-Pandit L, Vollan HK, Chin SF, Rueda OM, McKinney S, Osako T, Quigley DA, Kristensen VN, Aparicio S, Børresen-Dale AL, Caldas C, Langerød A.

Clin Cancer Res. 2014 Jul 1;20(13):3569-80. doi: 10.1158/1078-0432.CCR-13-2943. Epub 2014 May 6. Erratum in: Clin Cancer Res. 2015 Mar 15;21(6):1502.


A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.

Wang Y, Yin Q, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y.

Breast Cancer Res Treat. 2011 Nov;130(2):489-98. doi: 10.1007/s10549-011-1709-6. Epub 2011 Aug 12.


Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.

Liang DH, Ensor JE, Liu ZB, Patel A, Patel TA, Chang JC, Rodriguez AA.

Breast Cancer Res Treat. 2016 Jan;155(1):139-49. doi: 10.1007/s10549-015-3635-5. Epub 2015 Dec 14.


Supplemental Content

Support Center